Hamlin P, Farber C, Fenske T, et al. The dual SYK/JAK inhibitor cerdulatinib demonstrates complete inhibition of SYK and JAK and rapid tumor responses in a phase 2 study in patients with relapsed/refractory B cell malignancies. EHA 2017, abstract S773.
Trends in therapiegerelateerd MDS/AML na lymfoïde neoplasmata: 2000-2018
nov 2023 | Leukemie, Lymfoom, MDS